Supplementary Tables 1-16 from Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma

Supplementary Table 1: Atomic modelling, refinement, and validation statistics. Supplementary Table 2: Cryo-EM data collection and image analysis. Supplementary Table 3: Lymphoma cell lines evaluated in golcadomide study. Supplementary Table 4: Densitometry-based quantification of protein expression of selected markers within DLBCL cell line panel. Supplementary Table 5: Summary of the IC50 and proliferation AUC of lymphoma cell lines treated with golcadomide or other compounds. Supplementary Table 6: Genes with a significant modulation and temporal pattern in the golcadomide sensitive models. Supplementary Table 7: Pathway analysis of genes enriched for interferon signalling and immune system. Supplementary Table 8: BioMAP diversity plus panel result of golcadomide. Supplementary Table 9: Tissue distribution profile in rats treated with 10 mg/kg golcadomide. Supplementary Table 10: Plasma and brain pharmacokinetics of golcadomide in the OCI-Ly10 central nervous system lymphoma model. Supplementary Table 11. List of golcadomide enriched or depleted genes (FDR